The global single-cell analysis market was valued at USD 2.24 billion in 2020 and is expected to grow at a CAGR of 14.9% during the forecast period. Technological innovations in single-cell analysis products, increased government support for the cell-based study, expanding biopharmaceutical and biotechnology industries, widespread applications of single-cell analysis in oncology research, a rising focus on precision medicine, and the growing prevalence of infectious and chronic diseases are some of the factors driving the market growth.
Know more about this report: request for sample pages
Single-cell analysis is employed by pharmaceutical companies in drug discovery and development. The analysis will reveal the effects of the drug on DNA and protein levels, which will help in the pre-clinical development of the drugs. Hence, the use of single-cell analysis for such a vast market will hugely benefit its growth in the coming years.
COVID-19 is expected to further accelerate the growth of the market during the forecast period. Researchers across the globe are using single-cell analysis to understand the molecular mechanisms of COVID-19 better. For instance, researchers in the U.S. have collected tissues from 17 patients who died due to COVID-19.
They build a comprehensive “cell atlas” by analyzing various organs such as lungs, kidneys, liver, and heart, which will help understand the mechanism of organ failure in COVID-19 patients. In the future, the single-cell analysis market is expected to play an essential role in COVID-19 research and subsequent drug development process.
The increasing adoption of single-cell testing will drive the global market in diagnosing and monitoring diseases such as cancer and the growing adoption of the technique in various genomic analyses. Single-cell testing has emerged as a great tool in deciphering the molecular mechanisms of many diseases and in drug discovery and development.
Single-cell analysis has applications in the diagnosis of diseases such as cancer and pre-implantation genetic diagnosis. More than 19 million people were diagnosed with cancer in 2020, and the rise in new cancer every year is very alarming. By 2040, approximately 28 million new cases of cancer will be diagnosed each year.
The single-cell analysis technique can be employed to detect cancer at an early stage by analyzing circulating tumor cells from samples such as blood and urine since these circulating tumor cells will be found in the blood at a very early stage. Still, imaging technology can only detect cancer once the tumor has grown a considerable amount in size. The single-cell analysis will also help detect the specific mutation or biomarker in individual cancer patients, which will help develop personalized therapeutic strategies.
IVF procedures are gaining popularity worldwide due to increasing awareness and improved healthcare. More than 8 million babies were born through IVF by 2018, and in the U.S. alone, there are more than 450 fertility clinics. Single-cell analysis is gaining prominence in infertility clinics in pre-implantation genetic diagnosis (PGD), which is expected to increase the success rate of IVF. All these developments will boost the growth of the market in the coming years.
The increasing popularity of single-cell analysis has resulted in the growing launch of new platforms and products related to the market. Celsee, Inc. launched the Genesis system in 2018. This is a single-cell analysis platform developed to overcome the limitations in the already available single-cell analysis technology, such as lack of reproducibility and capture efficiency and problems associated with cell viability. The system has over 70% capture efficiencies and enhanced sensitivity when compared to other single-cell analysis technologies.
The companies are raising funds to develop new technologies. Recently in 2020, in a bid to develop cost-effective single-cell RNA sequencing kits, €6 million was raised by the Scipio bioscience in Series A funding.
Similarly, USD 70 million was raised by Mission bio to expand single-cell multi-omics technology known as Tapestri Platform that will be extremely useful in the development of cancer drugs. Many companies, such as Agios, use the platform, which will help in the simultaneous detection of protein and DNA changes in single cells.
The market is primarily segmented on the basis of product, application, workflow, end-use, and region.
Know more about this report: request for sample pages
The consumables segment generated the highest revenue in 2020, owing to the increased usability of products and regular purchasing of reagents, massive adoption of beads, and surging market demand for assay kits. The growing number of target diseases and the continuous need for consumables needed for the assays are driving the segment’s growth.
Furthermore, reagents and consumables are widely used in cell analysis assays, so market demand is often high. These reagents are available in various types, such as multicolor cocktails, markers, probes, and phenotyping agents. Thus, the acceptance and procurement of reagents generate high revenue in the market.
Installation of novel instruments and replacement of existing instruments has resulted in generating revenue for the instruments segment. Automated instruments contributed significantly to market sales due to their high-end functionality and technically sophisticated analytical options.
The cancer market segment dominated the market and generated the highest revenue in 2020. Single-cell analysis has proven to be useful for prior cancer cell diagnostics, driving the section. These techniques make it simple to identify mutation rates, cell proliferation conditions, and cell types.
A significant number of scientific entities examining single-cell proteomics and genomics to study various therapy categories like cancer, neuroscience, and infectious diseases has resulted in the increased use of single-cell analysis methods for diagnosis and treatment applications.
The growing use of stem cell therapies is helping the market for single-cell analysis. The broad range of stem cell therapies' applications is expanding the scope of stem cell proteomics, genomics, and epigenetics. The treatments like bone marrow transplants and hair regeneration are increasing the use of single-cell analysis market techniques.
The downstream analysis segment has gained momentum in recent years due to technological advances, such as the advent of next-generation sequencing for analyzing cell expressions. In addition, the industry is seeing an increase in artificial intelligence and machine learning in the data processing.
Numerous computational methodologies have been introduced and are being used because of their advantages, such as scalability, consistency, and increased success rates. As a result, the widespread use of such data analysis techniques would drive market growth over the coming years.
North America market is expected to be the most prominent region for the market in terms of revenue share owing to the adoption of advanced technologies in genomics and proteomics. Countries such as the U.S. funds heavily on medical research. The region has some of the biggest pharmaceutical and genomics companies in the world, which is expected to contribute to the market growth in the region.
Increasing personal healthcare spending, greater awareness, rapid adoption of new analytical methods, the availability of qualified professionals, exceptionally established healthcare systems, and the increasing expenditure on personalized medicine are some of the main driving factors for market development.
The Asia Pacific market is expected to be the fastest region for the market in terms of revenue share, owing to increased government funding, growing medical tourism industry, surging disposable income, and the presence of a large number of CROs in the countries like China and India that provide various drug discovery services.
Companies across the globe are investing heavily in R&D to develop new single-cell technologies owing to their increasing adoption in healthcare areas. The companies are undertaking acquisitions or raising funds to scale up their product and increase their foothold in the world's developing markets.
Some of the major players operating in the market include Qiagen NV, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Merck Millipore, Illumina Inc., Becton Dickinson & Company, 10x Genomics, Inc., Novogene Corporation, BGI, and Fluidigm Corporation.
Market size value in 2020
USD 2.24 billion
Revenue forecast in 2028
USD 6.56 billion
14.9% from 2021 - 2028
2016 - 2019
2021 - 2028
Revenue in USD million and CAGR from 2021 to 2028
By Product, By Workflow, By Application, By End-use, By Region
North America Europe Asia Pacific Latin America; Middle East & Africa
Becton, Dickinson and Company, Danaher Corporation, Merck KGAA, QIAGEN N.V., Thermo Fisher Scientific, Inc., 10x Genomics, Promega Corporation, Illumina, Inc., Bio-Rad Laboratories, Fluidigm Corporation, Agilent Technologies, Inc., Tecan Group Ltd., Sartorius AG, Luminex Corporation, Takara Bio, Fluxion Biosciences, Menarini Silicon Biosystems, Inc., bioMérieux SA, Oxford Nanopore Technologies, Cytek Biosciences, Corning Incorporated, Apogee Flow Systems Ltd., NanoCellect Biomedical, Rarecyte Inc, On-chip Biotechnologies Co., Ltd.